TOP: L–R: Ross Dobinson, Bruce Parncutt, Tim Oldham, Michael Kotsanis
BOTTOM: L–R: Sharon Papworth, Nina Webster, Felicia Colagrande
Ross Dobinson
BBus
Non-Executive Chairman
Ross has been a Director since 1998 and was appointed Chairman in January 2006 and then Executive Chairman from 1 July 2012 to October 2014. He is a founder and former CEO of Acrux. Ross has a background in investment banking and stockbroking. He is currently Managing Director of TSL Group Ltd, a corporate advisory company specialising in establishing and advising life sciences companies. He was a founding Director of Starpharma Holdings Limited (ASX: SPL) since May 1997, former Executive Chairman of Hexima Limited which was listed on the ASX from July 2010 to June 2011, former Chairman of TPI Enterprises Limited (ASX:TPE), a former Director of Roc Oil Company Limited (ASX: ROC) and a former Director of Racing Victoria Limited.
Bruce Parncutt
BSc, MBA
Non-Executive Director
Bruce joined the board on 30 April 2012. His career spans over 40 years’ in investment management, investment banking and stockbroking including seven years as Chief Executive of listed securities firm Mclntosh Securities (1990-1996) and three years as Senior Vice President of Merrill Lynch (1997-1999). His experience includes extensive involvement in financial analysis, merger and acquisition transactions, capitalraisings, and investment in companies across a broad spectrum from early stage to mature public companies. He holds a Bachelor of Science, an MBA, and is a Member of the Financial Services Institute of Australasia. Bruce is Chairman of the investment and corporate advisory firm Lion Capital. He is President of The National Gallery of Victoria and a Board Member of the NGV Foundation and the Australian Ballet Company. He was previously a Director of ASX listed Stuart Petroleum Limited (from Aug 2010 to May 2011) and was Director of Mclntosh Securities Limited, Australian Stock Exchange Ltd and Vision Systems Ltd for varying periods prior to 1 July 2010.
Tim Oldham
BSc.Hons, LLB Hons, PhD
Non-Executive Director
Tim joined the board in October 2013. He has more than a decade of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is CEO and Managing Director of Cell Therapies Pty Ltd, a leading Asia Pacific provider of collection, manufacturing, delivery and distribution capabilities for stem cell therapies and regenerative medicine and was President of Asia Pacific for Hospira Inc. (2007 to 2012), having held a variety of senior management roles with Mayne Pharma (2002 to 2007) prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of pharmaceuticals, devices, biologics and cellular therapies. Prior to this, Dr. Oldham was an engagement manager with McKinsey & Co (1997 to 2001). Tim has been chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Generic Medicines Industry Association and a member of the Pharmaceutical Industry Strategy Group. He is also a Director of iSonea Ltd (ASX: ISN).
Michael Kotsanis
BSc, MBus
Managing Director and Chief Executive Officer
Michael commenced as CEO and Managing Director of Acrux in November, 2014. He has over 25 years’ of experience in the pharmaceutical industry and has significant senior Ieadership experience across the global pharmaceutical markets. Michael was formerly the Chief Commercial Officer for Synthon Holding BV, a specialty pharmaceutical company based in The Netherlands, a position he held from mid-2010. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira, the global leader in generic injectable pharmaceuticals. Michael joined Hospira following its acquisition of Mayne Pharma in 2007, where he served as President Asia Pacific from 2002. He joined Mayne following their acquisition of Faulding Pharmaceuticals in 2001, where he held responsibility for commercial activities in Australia and New Zealand. Prior to Faulding, Michael held a variety of sales and marketing positions with Boehringer Ingelheim over an 11 year period. Michael earned a bachelor’s degree in science from Monash University, and a master’s degree in business from the University of Technology, Sydney.
Sharon Papworth
B.Com, CA
Chief Financial Officer and Company Secretary
Sharon commenced with Acrux as CFO and Company Secretary in September 2014. She has 18 years’ of finance experience, leading both commercial and technical functions. Having previously held senior finance roles at ASX and US listed organisations, Sharon’s experience spans across industries including Pharmaceuticals, Media, Fast Moving Consumer Goods and professional services. Prior to joining Acrux, Sharon was General Manager Finance at Salmat Limited (2010-2014) and Regional Financial Controller for Australia and New Zealand at Hospira (2004-2010), initially joining Mayne Pharma prior to its acquisition by Hospira. These roles supported business growth strategies, providing financial advisory and leadership. Sharon commenced her career at KPMG in the audit division and worked with a broad range of clients including ASX listed entities. Sharon is a Chartered Accountant who also holds a Bachelor of Commerce with majors in Accounting and Marketing.
Nina Webster
Ph.D., M.IP.Law, MBA
Commercial Director
Nina has over twenty years in the pharmaceutical industry, with leadership roles in business development, project management, intellectual property portfolio management, research and development and general management. Most recently, Nina spent two years with lmmuron Limited where, as Director of Commercialisation and Intellectual Property, she was responsible for the intellectual property portfolio and research & development. Prior to this, Nina spent ten years with Acrux Limited as Director of Business Development, responsible for the strategic identification, development and maintenance of commercial partnerships globally, and six years in research and development at Wyeth in the UK, gaining experience from formulation development through to pharmaceutical scale-up and technology transfer. Nina holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor degree in Pharmacology, a Masters degree in Intellectual Property Law from Melbourne University and an MBA from RMIT.
Felicia Colagrande
BSc(Hons)
Product Development and Technical Affairs Director
Felicia was appointed Product Development and Technical Affairs Director in February 2015. Felicia has a broad background in pharmaceutical operations, dermal drug development, quality control, analytical development and production. Felicia leads and facilitates all technical aspects of pharmaceutical product development including R&D, analytical development, clinical development, project management and CMC development, with a focus on exploiting and optimizing the company’s drug delivery technology. She has 25 years’ experience in the pharmaceutical/ biotech industry and joined Acrux in 2001. She has previously held positions at Faulding Pharmaceuticals, the Department of Clinical Pharmacology and Therapeutics at the Austin Hospital, Silliker- Microtech Laboratories and was an Adjunct Appointee Lecturer with the Faculty of Pharmacy and Pharmaceutical Sciences atMonash University. Felicia has a Bachelor of Science degree (with Honours) from La Trobe University.